Sunday, August 31, 2025
News Health
  • Health News
  • Hair Products
  • Nutrition
    • Weight Loss
  • Sexual Health
  • Skin Care
  • Women’s Health
    • Men’s Health
No Result
View All Result
  • Health News
  • Hair Products
  • Nutrition
    • Weight Loss
  • Sexual Health
  • Skin Care
  • Women’s Health
    • Men’s Health
No Result
View All Result
HealthNews
No Result
View All Result
Home Health News

Omidenepag Promising Against Glaucoma in Real-World Study

June 25, 2025
in Health News
Share on FacebookShare on Twitter


TOPLINE:

The daily use of eye drops containing 0.002% omidenepag isopropyl reduced intraocular pressure and was well‐tolerated in patients newly diagnosed with primary open‐angle glaucoma who had not previously received topical ophthalmic treatment.

METHODOLOGY:

  • Researchers conducted a phase 4 clinical trial at four eye centers in Korea to evaluate the effectiveness and safety of the drops in patients newly diagnosed with primary open-angle glaucoma.
  • Participants in the study had defects in their field of vision, had not previously received treatment for glaucoma, and had an intraocular pressure of 10-34 mm Hg; those with an intraocular pressure of ≤ 21 mm Hg were classified as having normal tension glaucoma.
  • Participants (N = 50) received one drop of 0.002% omidenepag isopropyl ophthalmic solution each evening for 12 weeks; adherence to the medication was assessed at weeks 4 and 12.
  • The primary endpoint of the trial was the change in intraocular pressure from baseline to week 12.

TAKEAWAY:

  • Among the enrolled participants, the effectiveness of omidenepag isopropyl eye drops was evaluated in the 37 patients who achieved at least 70% adherence to the medication, while safety was assessed in all 50 participants.
  • The mean intraocular pressure decreased significantly from 16.19 mm Hg at baseline to 13.55 mm Hg at week 12 (P < .0001), representing a 16% reduction; in the subgroup of patients with normal tension glaucoma, the mean intraocular pressure reduced from 15.79 mm Hg at baseline to 13.27 mm Hg at week 12.
  • The medication effectively reduced the mean intraocular pressure as early as week 4 (P < .0001).
  • The most common adverse events were hyperemia (13 cases) and iridocyclitis (5 cases), with no systemic reactions reported.

IN PRACTICE:

“Omidenepag isopropyl 0.002% ophthalmic solution had a rapid IOP-lowering effect as the percentage reduction from baseline was 15% at week 4,” the researchers wrote. “Omidenepag isopropyl 0.002% ophthalmic solution is suitable for first-line use at first diagnosis” of primary open-angle glaucoma, including in patients with normal tension glaucoma, they added.

SOURCE:

This study was led by Hyoung Won Bae, MD, PhD, of the Yonsei University Severance Hospital in Seoul, Korea. It was published online on June 17, 2025, in the Journal of Glaucoma.

LIMITATIONS:

This study lacked a control group and may have been subject to biases, as is common in observational studies. It also enrolled fewer participants than planned.

DISCLOSURES:

This study received funding from Santen Pharmaceutical Co., Ltd. All authors disclosed receiving honoraria from Santen.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.



Source link : https://www.medscape.com/viewarticle/omidenepag-promising-against-glaucoma-real-world-study-2025a1000h15?src=rss

Author :

Publish date : 2025-06-25 11:20:00

Copyright for syndicated content belongs to the linked Source.

Previous Post

Will You Be Prepared When Disaster Strikes?

Next Post

Generation Alpha’s coded language makes online bullying hard to detect

Related Posts

Health News

Remote ECG Screening Ups AF Detection ‘Modestly’

August 30, 2025
Health News

Year of Low-Dose DOAC Slashes Recurrence After Provoked VTE

August 30, 2025
Health News

Who Left the CDC This Week?

August 30, 2025
Health News

Trials Expand Evidence for Hypertrophic Cardiomyopathy Tx

August 30, 2025
Health News

Reducing Blood Pressure Meds in Older Adults Not Supported

August 30, 2025
Health News

Drug Affordability Worldwide; Trauma-Predictive Brain Networks

August 30, 2025
Load More

Remote ECG Screening Ups AF Detection ‘Modestly’

August 30, 2025

Year of Low-Dose DOAC Slashes Recurrence After Provoked VTE

August 30, 2025

Who Left the CDC This Week?

August 30, 2025

Trials Expand Evidence for Hypertrophic Cardiomyopathy Tx

August 30, 2025

Reducing Blood Pressure Meds in Older Adults Not Supported

August 30, 2025

Drug Affordability Worldwide; Trauma-Predictive Brain Networks

August 30, 2025

Is Warfarin Still an Option for Frail Patients With AF?

August 30, 2025

AI stethoscope could detect heart conditions in seconds

August 30, 2025
Load More

Categories

Archives

August 2025
MTWTFSS
 123
45678910
11121314151617
18192021222324
25262728293031
« Jul    

© 2022 NewsHealth.

No Result
View All Result
  • Health News
  • Hair Products
  • Nutrition
    • Weight Loss
  • Sexual Health
  • Skin Care
  • Women’s Health
    • Men’s Health

© 2022 NewsHealth.

Go to mobile version